Pfizer Inc. (PFE)

NYSE · New York, New York, USA · Founded 1849 · CEO Albert Bourla

Valuation summary

$29.34 fair value versus $27.54 in the market, a difference of +6.5%. Rated Hold.

Fair value per share$29.34
Current share price$27.54
Upside / downside+6.5%
Bear case$17.44
Bull case$46.04
Discount rate (WACC)8.9%
Terminal growth2.20%
Market capitalisation$157B
EV / Sales3.5x

About Pfizer Inc.

Founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn. Albert Bourla has been CEO since 2019 and oversaw the Comirnaty COVID-19 vaccine, which briefly made Pfizer the highest-revenue pharmaceutical company in the world before demand collapsed. The company spent much of that windfall on acquisitions, most significantly $43bn for Seagen in 2023 to build an antibody-drug conjugate oncology franchise. The central question is whether that pipeline can offset a heavy patent cliff.

Investment case

  • Seagen gives Pfizer a genuine position in antibody-drug conjugates, one of the most productive areas in oncology.
  • The dividend yield is among the highest in large-cap pharma and is covered by current cash flow.
  • Expectations are low enough that pipeline surprises are asymmetric to the upside.

Key risks

  • A severe patent cliff through the late 2020s affecting Eliquis, Prevnar and several others.
  • The COVID revenue collapse was faster and deeper than management guided, which damaged credibility.
  • Heavy debt load taken on to fund Seagen limits further business development.

Recent developments

Revenue by segment

Oncology27%
Primary Care26%
Specialty Care24%
Hospital & Other23%

Five-year forecast

RevenueFree cash flow
Year 1$63.9B$16.4B
Year 2$64.9B$16.2B
Year 3$65.9B$16.1B
Year 4$67.1B$15.9B
Year 5$68.5B$15.8B

What the street says

One of the more divided large-cap pharma names. Second-quarter 2026 results beat expectations, the revenue range was raised to $60.5–62.5bn and the CEO bought about $1m of stock in August; bears still point to the patent cliff, including Eliquis exclusivity loss around 2028, and a mixed acquisition record.

Comparable companies: GSK · ZTS · DHR · NVO · BMY · NVS · GILD · TAK

Open the interactive model, price chart and sensitivity grid →